MARKET

CDXS

CDXS

Codexis Inc
NASDAQ
4.151
+0.951
+29.70%
Opening 13:22 02/27 EST
OPEN
3.410
PREV CLOSE
3.200
HIGH
4.430
LOW
3.240
VOLUME
2.18M
TURNOVER
0
52 WEEK HIGH
5.07
52 WEEK LOW
1.450
MARKET CAP
289.83M
P/E (TTM)
-3.4353
1D
5D
1M
3M
1Y
5Y
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Helix Energy Solutions Group, Inc. Shares dipped 11% to $9.13 on Tuesday. The company posted weak earnings of 6 cents per share. Janux Therapeutics shares jumped 145% after the company announced updated clinical data for both of its clinical programs. Other stocks moving in Tuesday's mid-day session included Viking Therapeutic and Presto Automation.
Benzinga · 8h ago
Codexis Q4 2023 Earnings Preview
Seeking Alpha · 9h ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Janux Therapeutics (NASDAQ:JANX) stock increased by 189.9% to $43.78 during Tuesday's regular session. The company's market cap stands at $2.0 billion. Viking Therapeutic shares moved upwards by 91.96% as the company's Q4 earnings report came out.
Benzinga · 9h ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Janux Therapeutics stock rose 120.5% to $33.3 during Tuesday's pre-market session. The company's, Q4 earnings came out yesterday. Viking Therapeutic shares increased by 97.24% and TransMedics Gr stock rose 22.2%. NRX Pharmaceuticals shares decreased by 22.9% during the day.
Benzinga · 13h ago
PRGS, EVER and LVTX are among after hour movers
Seeking Alpha · 1d ago
Codexis stock climbs 11% on Roche licensing deal for DNA ligases
Codexis stock climbs 11% on Roche licensing deal for DNA ligases. The company announced it has granted an exclusive global license to Roche for its newly engineered double-stranded DNA ligase for next-generation sequencing library preparation. Under the deal, Codexis will receive upfront and milestone payments.
Seeking Alpha · 1d ago
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche
Codexis, Inc. Has entered into an agreement with Roche for an exclusive, global license for the Company's double-stranded DNA ligase for next-generation sequencing. Under the terms of the deal, Codexis will receive upfront and technical milestone payments. This deal supersedes the prior exclusive license on the EvoT4™ DNA lig enzyme.
Barchart · 1d ago
Weekly Report: what happened at CDXS last week (0219-0223)?
Weekly Report · 1d ago
More
About CDXS
Codexis, Inc. is an enzyme engineering company. The Company is engaged in discovering, developing and selling enzymes and other proteins. The Company commercializes its CodeEvolver enzyme engineering technology platform and products in the manufacture of small molecule pharmaceuticals. It operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Performance Enzymes segment consists primarily of two focus areas: biocatalysts for the sustainable manufacturing of pharmaceuticals, and enzymes for life science applications, including genomic sequencing and nucleic acid synthesis. The Novel Biotherapeutics segment offers product candidates include enzymes that are orally administered for function in the gastrointestinal tract (GI), such as its partnered product candidates CDX-7108 for the treatment of exocrine pancreatic insufficiency and CDX-6114 for the treatment of phenylketonuria, which are both in Phase I clinical trials.

Webull offers Codexis Inc stock information, including NASDAQ: CDXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDXS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CDXS stock methods without spending real money on the virtual paper trading platform.